INmune Bio Inc (INMB) Q4 2025 Earnings Call Transcript

Why It Matters

The announcements position INmune Bio at the forefront of neuroinflammation therapeutics while expanding its pipeline into high‑need CNS and oncology markets, underscoring a runway to advance multiple late‑stage trials.

Key Takeaways

• First patient dosed in XPro phase‑2 AD trial.
• MCI and mild AD trials target neuroinflammation biomarkers.
• TRD phase‑2 study funded by $2.9M NIH grant.
• INKmune platform pivots toward solid‑tumor indications.
• Cash runway extends to late 2023 despite $6.9M loss.

Pulse Analysis

INmune Bio’s XPro platform targets soluble TNF, a master regulator of neuroinflammation implicated in Alzheimer’s disease. By enrolling separate phase‑2 cohorts for mild AD and MCI, the company leverages advanced imaging and fluid biomarkers to de‑risk its program and accelerate toward registration. This biomarker‑centric approach aligns with industry trends that prioritize precision enrollment, potentially shortening trial durations and improving the likelihood of demonstrating cognitive benefit in early disease stages.

Beyond Alzheimer’s, INmune Bio is expanding its CNS portfolio with a phase‑2 trial in treatment‑resistant depression (TRD). Backed by a $2.9 million NIH grant, the study will assess XPro’s impact on reward‑pathway activity using functional MRI, alongside traditional depression scales. Success could validate soluble TNF inhibition across psychiatric indications, opening a sizable market of millions of patients with inflammation‑driven depression and reinforcing the company’s broader neuroinflammation strategy.

The firm’s INKmune platform, a cytokine‑free NK‑cell priming technology, is being repositioned toward solid‑tumor oncology, addressing a market far larger than hematologic malignancies. By enhancing NK‑cell survival and avidity in hypoxic, immunosuppressive tumor microenvironments, INKmune aims to overcome longstanding efficacy barriers. Coupled with a cash position of $66.7 million and a runway extending into late 2023, INmune Bio is well‑placed to fund these ambitious programs while delivering data that could reshape therapeutic approaches in both neurodegeneration and cancer.